Author name: Yali Friedman

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents […]

The purpose of this paper is to provide an update and report the current status of the cross-campus University of Colorado Denver program in bioinnovation and entrepreneurship, details of which were first reported in the Journal of Commercial Biotechnology in 2012⁵.  The paper outlines the joys and challenges of implementing an inter-campus program that attempts to marry cutting-edge biotechnology innovation with a solid business foundation.  The tremendous value offered by such a program, particularly to biotechnology and life-science researchers, is outlined. Operationalization and process issues such as differential tuition rates, distance between campuses, and class timing issues are considered, and solutions are offered.   Finally, recommendations are provided for other business schools considering a similar program.

Advances in commercial application of biotechnology worldwide over the past two decades have led to the development of a bioeconomy, whereby substantial economic outputs are from the development and use of biological materials. Bioeconomy encompasses all industries and economic sectors based on the values implicit in biological materials that can be translated into new sources of income, environmental sustainability and social well-being.

Malaysia, one of the most competitive biotechnology hubs in the Asia-Pacific region, has also taken critical early steps to coordinate and intensify national efforts to harness the potential of the bioeconomy. Most significantly, the Bioeconomy Transformation Programme (BTP) was launched in October 2012, making the country only the second in Asia, after China, and the first in ASEAN, to establish its own national bioeconomy initiative.

The BTP is in line with the Government’s objective to develop Malaysia into a high-income nation by the year 2020. The BTP aims to achieve this by focusing on bio-based industries in Malaysia, a sector that has been identified as having enormous potential to further develop the nation due to the abundance of natural resources available.

With the introduction of the BTP, Malaysia is now unlocking even greater opportunities in the local and regional biotechnology industry, and enhancing the participation of the private sector. Through effective execution strategies from the Government and BiotechCorp, the biotechnology sector is now directly contributing towards efforts to drive Malaysia towards a high-income and knowledge-based economy by year 2020.

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Biotechnology in India: Public–private partnerships

Go to paper

ABSTRACT: As the purpose of this study was a survey of public sector–private industry collaborations of the biotechnology sector in India, an organisational and functional overview of this sector was needed. Therefore, rather than studying a hypothetical biotech sector in India, the focus of this work was to study the public–private partnerships (PPP) that are occurring in India in the area of modern biotechnology…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Assessing the history and value of Human Genome Sciences

Go to paper

ABSTRACT: Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website

I was just notified of a fascinating paper citing my research from DrugPatentWatch.com. Briefly, I found two surprising results: Firstly, pharmaceutical innovation

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
What will it take to get institutional investors interested in life sciences again?
Go to paperABSTRACT: With the European biotechnology market nearing a…